Stabilized Tacrolimus Solid Dispersion for Degradation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Tacrolimus formulations face challenges with degradation products, particularly 8-epitacrolimus, due to its formation under mild conditions, which affects bioavailability and compliance with regulatory standards, and existing solid dispersions increase chemical degradation risk.
Innovation Solution
A stabilized pharmaceutical composition of tacrolimus with a pH-regulating stabilizing agent, such as tartaric acid, in a hydrophilic vehicle like polyethylene glycol, maintains a pH below 7, reducing 8-epitacrolimus formation and other degradation products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Difficulty of detecting and measuring
If tacrolimus is formulated as a solid dispersion to improve solubility and bioavailability, then bioavailability is improved, but the risk of chemical degradation increases
Solution Approach 1:
A stabilizing agent is introduced as an intermediary substance in the solid dispersion formulation. This stabilizing agent mediates between the tacrolimus and the solid dispersion matrix, preventing direct interactions that lead to degradation while maintaining the solubility-enhancing properties of the solid dispersion approach
Solution Approach 2:
The formulation utilizes parameter changes by controlling pH, moisture content, and physical state (amorphous vs crystalline) of the solid dispersion. By adjusting these parameters, the formulation achieves both improved solubility/bioavailability and reduced chemical degradation risk
2Device complexity
If pH is not controlled in the tacrolimus formulation, then formulation simplicity is maintained, but degradation product formation increases
Solution Approach 1:
pH is controlled as a critical parameter in the formulation by selecting excipients with appropriate pH-buffering capacities or by adding pH-adjusting agents. This parameter control prevents degradation reactions that are pH-sensitive, thereby reducing degradation product formation without significantly complicating the formulation
3Object-affected harmful factors
If strict regulatory control of degradation products is implemented, then patient safety is improved, but manufacturing and monitoring costs increase
Solution Approach 1:
Stability-enhancing measures are taken during the formulation design and manufacturing process itself, rather than relying solely on post-manufacturing testing and control. By building stability into the formulation through careful selection of excipients, pH control, and manufacturing conditions, the need for expensive post-manufacturing degradation control is reduced
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively prevents or reduces degradation products, ensuring stability and compliance with regulatory limits, enhancing bioavailability and shelf-life of tacrolimus formulations.
Implementation Method 1
The stabilizing agent is capable of providing a pH below 7 in the composition
Data Source
AI summary
The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising e stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.